PL3954384T3 - Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy - Google Patents

Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy

Info

Publication number
PL3954384T3
PL3954384T3 PL21195581.0T PL21195581T PL3954384T3 PL 3954384 T3 PL3954384 T3 PL 3954384T3 PL 21195581 T PL21195581 T PL 21195581T PL 3954384 T3 PL3954384 T3 PL 3954384T3
Authority
PL
Poland
Prior art keywords
prevention
diabetes treatment
stratification
genotype
genotype stratification
Prior art date
Application number
PL21195581.0T
Other languages
English (en)
Inventor
Anders Essen-Möller
Original Assignee
Diamyd Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamyd Medical Ab filed Critical Diamyd Medical Ab
Publication of PL3954384T3 publication Critical patent/PL3954384T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Rehabilitation Therapy (AREA)
  • Tropical Medicine & Parasitology (AREA)
PL21195581.0T 2017-09-08 2018-09-10 Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy PL3954384T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1751094 2017-09-08

Publications (1)

Publication Number Publication Date
PL3954384T3 true PL3954384T3 (pl) 2025-10-27

Family

ID=65634471

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21195581.0T PL3954384T3 (pl) 2017-09-08 2018-09-10 Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
PL18854165T PL3678692T3 (pl) 2017-09-08 2018-09-10 Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18854165T PL3678692T3 (pl) 2017-09-08 2018-09-10 Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy

Country Status (22)

Country Link
US (1) US20210077587A1 (pl)
EP (2) EP3954384B1 (pl)
JP (3) JP7337780B2 (pl)
KR (2) KR102607713B1 (pl)
CN (1) CN111372602A (pl)
CA (1) CA3074264A1 (pl)
CY (1) CY1124881T1 (pl)
DK (1) DK3678692T3 (pl)
EA (1) EA202090673A1 (pl)
ES (2) ES3038990T3 (pl)
HR (2) HRP20251067T1 (pl)
HU (2) HUE057216T2 (pl)
IL (2) IL273016B2 (pl)
LT (1) LT3678692T (pl)
MX (1) MX2020002462A (pl)
PL (2) PL3954384T3 (pl)
PT (1) PT3678692T (pl)
RS (2) RS62725B1 (pl)
SI (1) SI3678692T1 (pl)
SM (2) SMT202200009T1 (pl)
WO (1) WO2019050465A1 (pl)
ZA (1) ZA202206807B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) * 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
EP3873601A4 (en) * 2019-05-14 2022-03-23 Provention Bio, Inc. METHODS AND COMPOSITIONS FOR THE PREVENTION OF TYPE 1 DIABETES
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes
FI4069278T3 (fi) * 2019-12-06 2025-07-16 Dr Mary Morris & Ass Llc Menetelmiä ja koostumuksia tyypin 1 diabeteksen ehkäisemiseksi
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI923719A0 (fi) * 1992-08-19 1992-08-19 Jaakko Tuomilehto Detektering av susceptibilitet foer diabetes.
WO2005102374A2 (en) 2004-03-03 2005-11-03 Diamyd Medical Ab Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
JP2010525049A (ja) * 2007-04-24 2010-07-22 ダイアミド セラピューティクス アーベー 自己免疫疾患及び癌を治療する薬剤及び方法
SMT202000384T1 (it) * 2014-06-04 2020-09-10 Diamyd Medical Ab Acido glutammico decarbossilasi(gad)per l'uso nel trattamento di una malattia autoimmune
BE1023541B1 (de) 2014-06-05 2017-04-28 Bart Gerard Boucherie Bürstenstopfvorrichtung
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes

Also Published As

Publication number Publication date
PT3678692T (pt) 2021-12-29
IL273016B1 (en) 2024-06-01
LT3678692T (lt) 2022-01-10
EP3954384B1 (en) 2025-07-02
SMT202500348T1 (it) 2025-11-10
PL3678692T3 (pl) 2022-02-28
HRP20251067T1 (hr) 2025-11-07
CN111372602A (zh) 2020-07-03
EP3678692A1 (en) 2020-07-15
JP2024178205A (ja) 2024-12-24
EP3678692B1 (en) 2021-10-20
EP3954384A1 (en) 2022-02-16
HUE072917T2 (hu) 2025-12-28
HRP20211989T1 (hr) 2022-03-18
KR102781844B1 (ko) 2025-03-14
CA3074264A1 (en) 2019-03-14
DK3678692T3 (da) 2022-01-03
ZA202206807B (en) 2024-10-30
EA202090673A1 (ru) 2020-06-23
JP2020533306A (ja) 2020-11-19
US20210077587A1 (en) 2021-03-18
EP3954384C0 (en) 2025-07-02
KR20230167442A (ko) 2023-12-08
IL312528A (en) 2024-07-01
CY1124881T1 (el) 2022-11-25
JP7551848B2 (ja) 2024-09-17
JP7337780B2 (ja) 2023-09-04
IL312528B2 (en) 2026-07-01
MX2020002462A (es) 2020-09-22
EP3678692A4 (en) 2021-06-02
JP2023116726A (ja) 2023-08-22
KR20200051737A (ko) 2020-05-13
SMT202200009T1 (it) 2022-03-21
ES3038990T3 (en) 2025-10-16
HUE057216T2 (hu) 2022-04-28
IL273016A (en) 2020-04-30
IL312528B1 (en) 2026-03-01
SI3678692T1 (sl) 2022-04-29
RS62725B1 (sr) 2022-01-31
WO2019050465A1 (en) 2019-03-14
KR102607713B1 (ko) 2023-11-29
JP7850208B2 (ja) 2026-04-22
IL273016B2 (en) 2024-10-01
RS67218B1 (sr) 2025-10-31
ES2902075T3 (es) 2022-03-24

Similar Documents

Publication Publication Date Title
IL274217A (en) Adenovirus and its uses
IL274219A (en) Adenovirus and its uses
IL273016A (en) Genotype stratification in the treatment and prevention of diabetes
IL259570A (en) Combined therapy and their uses and methods
IL257706A (en) Peptidomimetic macrocycles and their uses
PL3240554T3 (pl) Blautia stercosis i wexlerae do stosowania w leczeniu chorób zapalnych i autoimmunologicznych
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
SG11201802925YA (en) Integrated visual morphology and cell protein expression using resonance-light scattering
IL254977B (en) Biological conjugates and their uses
IL254444A0 (en) Peptidomimetic macrocycles and their uses
HUE070659T2 (hu) KDM1A inhibitor és annak felhasználása terápiában
GB201511382D0 (en) Novel compounds and their use in therapy
IL274220A (en) Adenovirus and its uses
GB201507721D0 (en) Immunosuppressive agents and their use in therapy
GB201604213D0 (en) Drug combination and its use in therapy
SMT202200151T1 (it) Composizioni e metodi per l’uso nel trattamento di omocistinuria.
SI3406258T1 (sl) Zdravilo za zdravljenje putike
PL3212280T3 (pl) Dopasowanie szumu usznego u pacjentów z implantem ślimakowym (CI) i implantem słuchowym pnia mózgu (ABI)
EP3271464A4 (en) Mirna mimetics and their use in treating sensory conditions
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
GB201521209D0 (en) Title and application in german
IL271555A (en) Combining its uses and treatments
GB201511158D0 (en) Cell modification and application in therapy
GB201702652D0 (en) Delta-theraphotoxin-Ac1 for use in treating diabetes
GB2545167B (en) Cloches and use thereof